Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.55 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.55 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | EBP | Q15125 | 1/20 | 0.40 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901787 | 0.98 | GNAI3 (0.52) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL4630069 | 0.92 | GNAI3 (0.44) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL3952603 | 0.83 | DRD2 (0.39) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL1043420 | 0.82 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL7991671 | 0.82 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL18630997 | 0.82 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL7022103 | 0.82 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL11571907 | 0.82 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL1043024 | 0.82 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL18092757 | 0.82 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1820799-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | GABRA5, GABRA1, GABRB1 | GNAI3 1131/4885GNAO1 1472/4885GNAI1 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.